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ABSTRACT
Objectives: Our purpose was to assess the cost-effectiveness
of intraperitoneal chemohyperthermia (IPCH) compared to
palliative chemotherapy (STANDARD) against peritoneal
carcinomatosis arising from colorectal cancer.
Methods: We performed a retrospective study of 96 patients
whose peritoneal carcinomatosis had been diagnosed
between January 1998 and December 2003 and treated either
with IPCH or with palliative chemotherapy in French com-
prehensive cancer centers. Patients were followed up over a
3-year period. Effectiveness was measured by restricted mean
survival at 3 years. The Bang and Tsiatis method was used to
handle cost-censored data. The conﬁdence limits of the mean
cost per patient in each group and the mean incremental cost
per life-year saved were computed using 1000 bootstrap
replicates. We also computed an acceptability curve for the
incremental cost-effectiveness ratio (ICER).
Results: We found that IPCH improved survival and was
more costly than STANDARD treatment. Over a 3-year
observation period, IPCH yielded an average survival gain of
8.3 months at the additional cost of €58,086 (95% conﬁ-
dence interval 35,893–112,839) per life-year saved.
Conclusion: The ICER of IPCH is acceptable given the sever-
ity and burden of peritoneal carcinomatosis for which there is
no alternative curative treatment.
Keywords: cost-censored data, cost-effectiveness, intraperito-
neal chemohyperthermia, peritoneal carcinomatosis from
colorectal cancer, restricted mean survival.
Introduction
Peritoneal carcinomatosis (PC) is present in approxi-
mately 10% of colorectal cancer at initial diagnosis
and in 25% of patients with recurrent disease [1]. PC
is a very lethal condition. No curative treatment was
available until oncology surgeons developed an inno-
vative therapy in the 1990s combining complete
cytoreductive surgery of all macroscopic/gross disease
with hyperthermic chemotherapy. This procedure
named intraperitoneal chemohyperthermia (IPCH, or
intraperitoneal hyperthermic chemotherapy) was ﬁrst
developed by Sugarbaker [2]. Phase II studies sug-
gested the efﬁcacy of IPCH in terms of survival
improvement [3–9]. A phase III randomized controlled
trial published in 2003 [10] showed that IPCH halved
the risk of death when compared to systemic chemo-
therapy (5-ﬂurouracil-leucovorin followed by irinote-
can) in PC of colorectal origin. In that study, the
hazard ratio was 0.55 (95% conﬁdence interval [CI]
0.321–0.951). Median survival with systemic chemo-
therapy was 12.6 months versus 22.3 months with
IPCH. The completeness of cytoreductive surgery was
the most important prognostic factor [11]. As IPCH is
an innovative therapy, economic evaluations based on
individual data collection are lacking. In a recent lit-
erature review from the UK Health Technology Assess-
ment Agency [12], only one study evaluating the cost
of IPCH in patients with pseudomyxoma peritonei was
identiﬁed. The study was based on 25 cases treated in
a US setting. Estimated treatment costs were €130,000
[13]. In a recent study [14], we assessed the cost of
IPCH based on all procedures performed during a
two-year period at our institution, whatever the origin
of PC (mainly colorectal and pseudomyxoma perito-
nei). The mean cost of the hospital stay was €39,358
(SD €31,853). This procedure has not been added to
the patient classiﬁcation scheme under the new French
Prospective Payment System and half its cost is reim-
bursed. In 2003, based on scientiﬁc evidence on the
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efﬁcacy of IPCH, the French Ministry of Health
decided to promote IPCH, by allocating ﬁnancial
support to selected surgical teams, and to assess its
cost-effectiveness. It was not possible to perform a new
randomized controlled trial [15] to assess the survival
beneﬁt, because the procedure had already demon-
strated its efﬁcacy in the 2003 trial [10]. We therefore
used a retrospective comparison. Our objective was to
assess the incremental cost-effectiveness ratio (ICER)
of IPCH compared to palliative chemotherapy against
PC of colorectal origin.
Patients and Methods
Study Design and Patient Selection
We performed a retrospective study on selected
patients with colorectal PC treated either with IPCH or
with palliative chemotherapy between January 1998
and December 2003 in six French comprehensive anti-
cancer centers. The IPCH group consisted of all con-
secutive patients with colorectal PC having undergone
IPCH in a single-institution, which was the French
reference center for the technique. Forty-eight patients
were identiﬁed. The control population consisted of
comparable patients who had been treated in ﬁve com-
prehensive anticancer centers with standard chemo-
therapy combined or not with palliative surgery
(STANDARD group). These patients did not beneﬁt
from IPCH because the technique was unavailable in
these centers and because patients could not be
referred to the reference center because of its limited
treatment capacity. Patients were highly selected to
ensure comparability with IPCH patients. The selec-
tion process was divided into two steps. During the
ﬁrst step, medical investigators selected from their
records of all patients with colorectal PC diagnosed
between January 1998 and December 2003 who had
been treated with palliative chemotherapy and who
met eligibility criteria. Patient eligibility was deﬁned
according to the six criteria deemed good prognostic
factors for IPCH in the literature [15,16]: 1) a good
general status (Eastern Cooperative Oncology Group
Status 1–2); 2) age less than 65 years; 3) no extra-
abdominal extension; 4) no evidence of bowel obstruc-
tion; 5) no tumor larger than 2 cm at computed
tomography; 6) no rapid progression of PC under sys-
temic chemotherapy. During the second step, the prin-
cipal investigator double-checked the medical records
of the potentially eligible patients provided by the
centers (75 patients), by recontacting the investigators
to ensure that the eligibility criteria had been applied
homogeneously. Forty-eight patients were ﬁnally
selected. During double-checking, the investigator was
blinded to the detailed characteristics of the IPCH
patients. The fact that there was exactly the same
number in both groups was purely coincidental.
Cost Data
Cost computation focused on inpatient care. In each
group, all PC-related hospital stays were recorded over
a 3-year period since the diagnosis of PC. The reason
for admission and the duration were recorded for each
hospital stay. For chemotherapy-related stays, the drug
and dose were also recorded. IPCH stays were valued
using a microcosting approach. For each IPCH stay,
the duration of the IPCH procedure, type and dose of
IPCH agents (5-ﬂuorouracil, irinotecan, and/or oxali-
platin), and the number of admissions days per ward
type (intensive care and surgical ward) were recorded.
Unit costs were extracted from the accounting data
(year 2002) at the center where procedures had been
performed: the cost of 1-hour use of the operating
room, the cost of 1 mg of each chemotherapy agent,
the cost of a bed day in a surgery unit, and the cost of
a bed day in an intensive care unit. All other hospital
stays in both groups were costed using the duration of
hospital stay recorded in the study. According to the
diagnosis-related group (DRG) in which the stay was
classiﬁed, the duration of hospital stay was multiplied
by the average cost per day of the given DRG, and
derived from the 2004 French National Hospital Costs
Survey (period 2001–2002). The full cost covers all
expenditures related to a given stay: physician, nurses
and other staff salaries, medication and medical
devices, lab tests and other diagnostic procedures,
depreciation of equipment and overheads. We pro-
ceeded in a different manner for chemotherapy stays.
We excluded the medication costs from the average
cost of the DRG, because we had a detailed record of
the drugs used. We therefore valued the use of chemo-
therapy agents directly from data recorded in the study
(type of agents and dose) and unit costs in our institu-
tion in 2005. The main unit costs used are summarized
in Table 1.
Cost Analysis
Mean inpatient costs were assessed from the perspec-
tive of the payer for the whole study period. As the
study was retrospective and concerned the 1998–
2003 period, we did not collect data on workdays
lost to avoid major memory biases for the earlier
years. In addition, questioning families about
deceased patients was likely to be highly unreliable
and also unethical.
In the presence of cost-censored data, the mean of
the costs observed is biased downwards because costs
occurring after censoring are unknown. In the 90s,
methods were proposed to deal with cost-censored
data [17,18]. In each group, we used the partitioned
estimator proposed by Bang and Tsiatis [18] to adjust
for censoring of costs. The Bang and Tsiatis method
consists in subdividing the study period into K inter-
vals of time (tj,tj+1)1jK. For each interval, average costs
are estimated as the sum of the costs Mij observed
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(IPCH procedure cost excluded) during this interval
divided by the population size n. This “average” cost
estimate is weighted by the probability Kˆj of not being
censored at the beginning of the period calculated by
the Kaplan–Meier method. This results in attributing
costs for censored patients. The estimated average
total cost for the study period is thus obtained by
summing the costs across all intervals. The partitioned
estimator is deﬁned by:
ˆ
ˆμ =
==
∑∑1
11n
M
K
i
j
ij
jj
K
i
n Δ
(1)
Δij = 1 if the patient i is not censored at the beginning
of the interval j. Our data were detailed enough to use
a 1-month interval.
Survival Analysis
The effectiveness measure used was the number of
years of life saved. As patients were still alive after
3 years of follow-up in both groups, we used the dif-
ference between restricted mean survivals at 3 years to
evaluate the beneﬁt of IPCH. Survival was estimated
by the Kaplan–Meier method, which uses all available
information including the observed survival time for
censored data. To measure health beneﬁts, economists
use life expectancy, which is the mean survival m
deﬁned by:
μ =
∞∫ S t dt( )0 (2)
where S(t) is the Kaplan–Meier estimate of the survival
probability.
The true mean survival is represented by the area
under the Kaplan–Meier curve when all the patients
were deceased. In the case of censored data, the reli-
ability of S(t) declines with t as the number of patients
declines both as a result of deaths and censored obser-
vations. Therefore, the size of the CI of S(t) increases as
the number of patients at risk decreases. To deal with
this difﬁculty, Irwin [19] suggested estimating the
mean survival restricted to a suitably chosen time T*
called the point of restriction. The restricted mean
survival mR is represented by the area under the curve
up to T* and is deﬁned by:
μR
T
S t dt= ∫ ( )0 * (3)
To determine the point of restriction T*, Karrison [20]
advised using the largest time point such that the stan-
dard error of the survival estimates SE(S(t)) at this
point in each group is within 5% to 10%. He proposed
using the following Peto et al. [21] formula to estimate
the standard error:
SE S t S t S t n t( ( )) ( ) ( ( )) / ( )= −1 (4)
where n(t) is the number of patients at risk at t.
Restricted mean survival was measured from the date
of the diagnosis of PC until death or the date of the last
follow-up in censored data or T* for noncensored
data. The difference between restricted mean survivals
was tested with a two-sided log rank test.
Statistical and Sensitivity Analyses
We used Student’s t-tests to compare continuous vari-
ables and chi-square tests to compare distributions of
dichotomous variables. To handle uncertainty, we used
a bias-corrected accelerated nonparametric bootstrap
method [22] to estimate a 95% CI for mean costs in
Table 1 Unit costs data (in €) and number of hospital stays in each group
Unit cost
Number of stays
IPCH STANDARD
IPCH stays (microcosting) 48 0
1 hour use of the operating room 394
Mean cost of intraperitoneal chemotherapy drugs 3081
Bed day in a surgery unit 431–642
Bed day in an intensive care unit 1389
Other hospital stays (costs per DRG)
Chemotherapy 883 726
DRG for CT given in an inpatient setting (daily cost)* 448
DRG for CT administered in an outpatient setting* 350
Chemotherapy agents
Range of costs per course for all agents 8–888
Cost per course for Folﬁri-Folfox regimens 332–343
Surgery (IPCH excluded) 52 48
Daily cost for the three most frequent DRGs
Rectum resection with associated comorbidities 650
Digestive surgery with associated comorbidities 608
Major surgery of the bowel or colon without comorbidities 567
Palliative care and disease progression 34 103
DRG for palliative care 6067
All hospital stays 1017 877
*Chemotherapy agents excluded.
CT, chemotherapy; DRG, diagnosis-related group; IPCH, intraperitoneal chemohyperthermia.
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each group and for the ICER and to compute a cost-
effectiveness acceptability curve. The acceptability
curve represents the probability that IPCH will be
cost-effective for a wide range of threshold values. One
thousand resamplings of the study population were
performed. Although the retrospective group was
selected through a thorough scrutiny of medical
records, we still had to control for any residual selec-
tion bias. We performed a Cox regression analysis to
predict the impact of patient characteristics on survival
and to test the need to integrate signiﬁcant variables in
a sensitivity analysis.
Results
Demographic and clinical characteristics are presented
in Table 2. All characteristics were comparable except
age and tumor differentiation. IPCH patients were sig-
niﬁcantly younger. There was no difference in systemic
chemotherapy, either in the type of agents used or in
the number of lines administered in each group (102
vs. 110, P = 0.52). In the IPCH group, intraperitoneal
chemotherapy was oxaliplatin in 30 patients and
oxaliplatin combined with irinotecan in the remaining
18 patients. In both groups, three types of PC-related
hospital stays were observed: surgery (IPCH or other
type), chemotherapy, and palliative care (Table 1). In
the STANDARD group, 877 hospital stays were
recorded: 48 for surgery (36 at diagnosis of PC and 12
subsequent operations in those 36 patients), 726 for
chemotherapy, and 103 for other reasons (mostly
digestive DRGs and palliative care). For the remaining
12 patients who had not undergone palliative surgery,
PC had been diagnosed either by imaging (8 patients)
or at histological analysis (4 patients). In the IPCH
group, 1017 hospital stays were recorded: 48 stays
for IPCH, 52 for surgery (before or after IPCH), 883
for chemotherapy (before and after IPCH), and 34 for
IPCH complications or disease progression. The mean
number of admissions to hospital per patient was 21.2
(range: 1–50) in the IPCH group and 18.3 (range:
3–47) in the STANDARD group (P = 0.17). The cost
of the hospital stay for IPCH was estimated at €33,659
(95% CI 30,571–36,747). On average, the IPCH pro-
cedure lasted 9 hours (range: 6–13) and its cost was
estimated at €9098 (95% CI 8680–9516). The mean
cost of IPCH drugs was €3081 (95% CI 2879–3284)
and accounted for one-third of the cost of the proce-
dure. On average, the duration of the hospital stay was
25 days, including 12 days in the intensive care unit.
The cost of the stay in clinical wards was €24,561
(95% CI 21,426–27,696). Using Bang and Tsiatis’ esti-
mator, the total inpatient cost per patient over a 3-year
period was estimated at €81,481 (95% CI 73,618–
91,410) in the IPCH group and at €40,821 (95% CI
35,437–48,516) in the STANDARD group. Table 3
details the observed cost per type of hospital stay in
both groups; these estimates have not been corrected
for censoring. Figure 1 shows the distribution of costs
observed in both groups (uncorrected for censoring).
Three years after the diagnosis, median survival had
not been attained in the IPCH group whereas it was
24.8 months in the STANDARD group (P < 0.0001,
two-sided log rank test). The 3-year overall survival
probability was 72% (95% CI 57–83%) for IPCH
patients and 32% (95% CI 20–48%) for patients in
the STANDARD group. The hazard ratio was 0.29
(95% CI 0.15–0.55) in favor of IPCH. At 3 years, the
standard error of the survival estimate SE(S(t)) was 8%
in the IPCH group and 9% in the STANDARD group.
Thus, with this time point, Karrison’s criterion was
fulﬁlled. At 3 years, restricted mean survival was
estimated at 31.7 months in the IPCH group and
23.4 months in the STANDARD group. Thus, IPCH
Table 2 Patient characteristics at peritoneal carcinomatosis
diagnosis
IPCH
(n = 48)
STANDARD
(n = 48) P
Females (%) 36 34 0.8
Mean age (year) 46 51 0.01
Site of cancer 0.8
Colon 40 41
Rectum 8 7
Initial pT staging 0.08
T1,T2 0 3
T3 23 18
T4 25 24
Not reported 0 3
Lymph node status 0.07
N+ 34 31
N– 14 12
Not reported 0 5
Tumor differentiation 0.02
Well 37 29
Poor 11 12
Not reported 0 7
Extension of PC 0.07
Limited 27 26
Extended 21 17
Not reported 0 5
CEA rate (ng/ml) 0.1
<30 33 40
30 15 8
Total number of lines of chemotherapy 102 110 0.52
CEA has a potential predictive value in PC arising from cancer.
CEA, carcinoembryonic antigen; IPCH, intraperitoneal chemohyperthermia; PC, peri-
toneal carcinomatosis.
Table 3 Mean inpatient costs per patient (observed costs in €)
Type of hospital stay IPCH (n = 48) STANDARD (n = 48)
Hospital stay for IPCH 33,659 (10,635) 0
Hospital stays for
chemotherapy
28,967 (16,807) 21,457 (13,515)
Hospital stays for other
reasons
14,898 (15,224) 13,036 (14,986)
All hospital stays 77,524 (29,031) 34,493 (19,098)
Standard deviations are reported in parentheses.
IPCH, intraperitoneal chemohyperthermia.
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resulted in a mean survival gain of 8.3 months
(or 0.7 years). Kaplan–Meier curves are shown in
Figure 2. The cost per life-year saved was €58,086 (cf.
Table 4). The CI for the ICER obtained by performing
1000 bootstrap replicates was 35,893–112,839.
Figure 3 shows the costs and the effectiveness obtained
for each bootstrapped sample. All cost-effectiveness
values are located in the northeast quadrant meaning
that IPCH improved survival at a higher cost. Seventy-
ﬁve percent of ICERs were less than €70,000 per
life-year saved (cf. Fig. 4). IPCH and the extent of
carcinomatosis were the only prognostic factors
singled out in the Cox regression analysis (adjusted
hazard ratios were, respectively, 0.19 and 0.26). The
extent of carcinomatosis was comparable in the two
groups and was therefore not likely to inﬂuence the
cost-effectiveness ratio.
Discussion
Our objective was to assess the cost-effectiveness of
IPCH compared to standard treatment with palliative
chemotherapy. We used retrospective data concerning
96 patients over a 3-year period after the diagnosis of
PC. Although our study is the ﬁrst to assess IPCH
cost-effectiveness, some limitations must be men-
tioned. The major limitation is the question of conﬁ-
dence in survival results based on a nonrandomized
study. Our study was not randomized because it would
have been unethical to do so. IPCH was proposed as
the last recourse for the cure of PC. The procedure has
been performed for more than 10 years at the Institut
Gustave Roussy (French reference center for the tech-
nique) even though its efﬁcacy had not been proven in
a randomized trial until 2003. Verwaal et al. did,
however, demonstrate improved survival with IPCH in
a controlled setting [10]. In our study, we attempted to
address the selection bias. All consecutive patients with
colorectal PC were included in the IPCH group. In the
STANDARD group, patients were highly selected to
ensure comparability with IPCH patients. Character-
istics were similar except for age and tumor differ-
entiation. Nevertheless, when we applied a Cox
regression model to our data, it showed that the sur-
vival beneﬁt was not sensitive to age and tumor differ-
entiation. Finally, a potential selection bias in our
study may be due to the identiﬁcation of the patients.
IPCH patients were identiﬁed through the IPCH pro-
cedure item whereas patients in the STANDARD
group were identiﬁed through their diagnosis of PC.
The fact that IPCH patients were selected through the
IPCH item signiﬁes that these patients had lived until
the IPCH procedure. The median interval between the
diagnosis of PC and IPCH was 9 months. This median
interval could have led to an overestimation of survival
in this group [23]. We checked that each IPCH patient
was matched with a STANDARD patient on the fol-
lowing criterion: the time interval from diagnosis until
death for a STANDARD patient was at least equal to
the interval from the diagnosis to IPCH for the IPCH
patient. This bias should therefore be minimized.
, , , , , , , , , , , ,
Figure 1 Distribution of total inpatient
costs (observed costs). IPCH, intraperitoneal
chemohyperthermia.
Figure 2 Overall survival in intraperitoneal chemohyperthermia (IPCH)
and STANDARD groups.
Cost-Effectiveness of IPCH 351
Potential biases in the method must also be underlined.
First, restrictedmean survival was used as an estimation
of the treatment beneﬁt. Although this measure appears
to be conservative, it may underestimate the treatment
beneﬁt. Second, Bang and Tsiatis’ method was used to
handle cost-censored data. As thereweremore censored
data in the STANDARD arm in the proportion of
nondecreased patients, the ICER of IPCH was lower
using Bang and Tsiatis’ estimates. Third, our cost esti-
mate omitted ambulatory costs as well as indirect costs.
But it was difﬁcult to collect these types of costs retro-
spectively. For ambulatory care, claims data from the
Sickness Fund are only kept for an 18-month period,
which excluded our study patients. Questioning fami-
lies about the use of medical resources for events that
happened 2 or more years ago was not reliable and
particularly difﬁcult for this lethal condition. We there-
fore focused our analysis on inpatient care for which
information on costs was available. The severity of the
condition implies that most outpatient and inpatient
care was ensured by specialized institutions and in
comparison, ambulatory care costs in doctors’ ofﬁces
can be assumed to be marginal. Finally, taking into
account the impact on productivity of workdays lost
may increase the ICER, since patients who had ben-
eﬁted from IPCHexperiencedmore hospital admissions
during the follow-up period than standard patients, but
this needs to be corroborated by data.
Health economists are always faced with the issue of
concluding whether or not a treatment strategy is cost-
effective. We attempted to show that although IPCH is
a resource intensive treatment (€33,659 [30,571–
36,747]), the ICER €58,086 (35,893–112,839) is
acceptable given the severity and the burden of PC. A
widespread reference used to position the ICER result is
the yearly cost of dialysis, which was recently estimated
at €54,000 in France (Biomedical Agency website:
http://www.agence-biomedecine.fr). We also selected
three recent examples with proven high internal and
external validity and whose disease severity is compa-
rable to that of PC in terms of the prognosis: liver
transplant versus no transplant, imatinib in unresect-
able metastatic gastrointestinal stromal tumors (GIST),
and trastuzumab (including HER-2 testing) in meta-
static breast cancer. In these studies, the ICERs were
expressed as the cost per quality-adjusted life-year
rather than as the cost per life-year saved. Nevertheless,
some authors pointed out that quality adjusting does
not substantially alter cost-effectiveness results [24,25].
The ICERs for liver transplant versus no transplant
ranged between €31,000 and €70,000 [26]. In GIST
[27], the ICER of imatinib compared to the best sup-
portive care was estimated at between €75,000 and
€146,000. The ICER of trastuzumab compared to stan-
dard chemotherapy (with no HER-2 testing) ranged
from €103,000 to €120,000 depending on the com-
bination of tests performed to establish the HER-2
status [28]. We conclude that IPCH is a cost-effective
treatment in selected PC patients. Such a conclusion
should have funding implications. In the French
Prospective Payment System, no speciﬁc DRG exists
for IPCH and the current tariff is far below the cost of
the hospital stay for IPCH.
Table 4 Cost-effectiveness results
IPCH STANDARD Differential ICER
Mean cost (in €) 81,481 40,821 40,660
Mean cost (in €; IPCH stay excluded) 47,822 40,821 7,001
Restricted mean survival (in years) 2.6 1.9 0.7
Mean cost per life-year saved (in €) 58,086
ICER, incremental cost-effectiveness ratio; IPCH, intraperitoneal chemohyperthermia.
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Figure 3 One thousand bootstrap replicates of the cost-effectiveness
ratio. Figure 4 Cost-effectiveness acceptability curve.
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